Resumen Ejecutivo del tratamiento antibiótico domiciliario endovenoso: Directrices de la Sociedad Española de Enfermedades Infecciosas y la Sociedad Española de Hospitalización a Domicilio

Outpatient parenteral antimicrobial therapy (OPAT) programmes make it possible to start or complete intravenous antimicrobial therapy for practically any type of infection at home, provided that patient selection is appropriate for the type of OPAT programme available. Although the clinical management of infections in the home setting is comparable in many respects to that offered in conventional hospitalization (selection of antibiotics, duration of treatment, etc.), there are many aspects that are specific to this care modality. It is essential to be aware of them so that OPAT continues to be as safe and effective as inpatient care. The objective of this clinical guideline is therefore to provide evidence-and expert-based recommendations with a view to standardizing clinical practice in this care modality and contribute to a progressive increase in the number of patients who can be cared for and receive intravenous therapy in their own homes.Los programas de tratamiento antibiótico domiciliario endovenoso (TADE) permiten iniciar o completar el tratamiento antimicrobiano por vía endovenosa de prácticamente cualquier tipo de infección en el domicilio, siempre y cuando se realice una selección del paciente acorde al tipo de programa de TADE que se dispone. Aunque hay aspectos del manejo clínico de las infecciones en el domicilio que son superponibles en la mayoría de los casos a la realizada en la hospitalización convencional (selección de la antibioterapia, duración del tratamiento, etc.), existen numerosos aspectos que son específicos de esta modalidad asistencial. Resulta imprescindible conocerlos para que el TADE siga siendo igual de eficaz y seguro que la hospitalización convencional. El objetivo de esta guía clínica es por tanto proporcionar recomendaciones basadas en la evidencia realizadas por expertos para homogeneizar la práctica clínica de esta modalidad asistencial y contribuir a que se incremente progresivamente el número de pacientes que pueden ser atendidos y recibir tratamiento endovenoso en su propio domicilio

Protein-only Nanoparticles for T Cell Expansion and Activation

Altres ajuts: acords transformatius de la UABThis work was funded by the Spanish Ministry of Science and Innovation (PID2019-105017RB-I00), by ICREA, ICREA-Academia 2020, to S.V., and by Fundación Contigo Contra el Cáncer de la Mujer (#BREASTILs. Functional Study of TILs from breast cancer patients: an approach to personalized medicine) to M.M. M.F.-S. was supported by the Spanish Ministry of Science and Innovation (FPU20/02897). G.L.B. was supported by the Universitat Autònoma de Barcelona (PIF 2021-22 B21P0025). M.G.-G. was supported by the Spanish Ministry of Science and Innovation (FPU16/02465). A.A. was supported by Fundación Contigo Contra el Cáncer de la Mujer. J.G-P. was supported by the Spanish Ministry of Science and Innovation with a Juan de la Cierva Incorporación IJC2019-041039-I. The authors thank the members of the Microscopy Service of the Universitat Autònoma de Barcelona for their technical support in electron microscopy and confocal imaging. We also thank the Cell Culture, Antibody Production and Cytometry Service and, specially, Manuela Costa for the technical support in Flow Cytometry analyses. We thank Andrea Livieri for her help in endotoxin measurements.The in vitro expansion and activation of T cells utilizing synthetic nanosized artificial antigen presenting cells (aAPCs) have emerged as a promising technique for cancer treatment. Although diverse nanomaterials have been explored as aAPC scaffolds, protein-only nanoparticles have been largely overlooked, despite their high designability and biocompatibility. In this study, we exploit a plug-and-play approach for the development of protein-only nanoparticles as aAPCs using the self-assembling properties of ZapB coiled coil and the Z-domain antibody-capturing ability. The resulting coiled coil-based nanoparticles (ccNPs) can be easily, rapidly, and simultaneously functionalized with anti-CD3 and anti-CD28 antibodies (ccNPs-CD3/CD28). Our results demonstrate that ccNPs-CD3/CD28 induce polyclonal T cell proliferation and activation while sustaining cytokine production for an extended period. The biocompatibility, modularity, and chemistry-free surface modification of this protein-only strategy render it a versatile platform for in vitro T cell expansion and activation